Drug Discovery
By
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…
Sanofi’s $1.53B Sino Biopharm Pact: Strategic Power Play or China-Derisked Bet?
Sanofi’s March 3, 2026, licensing of Sino Biopharm’s rovadicitinib—a JAK1 inhibitor approved in China for first-line myelofibrosis—upfront $135M…
GLP-1s: The Thrilling Game-Changer in Obesity—Why Insurers Are Throwing Open the Reimbursement Gates
GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are electrifying the obesity market with unprecedented 15-25% sustained…
How Does Novo Nordisk Transform Metabolic Leadership Into Multi-Billion Dollar Dominance Through 2030?
Novo Nordisk executes a “multi-mechanism obesity fortress” strategy under new CEO Mike Doustdar, reallocating R&D firepower from discontinued cell therapies…
How Does AstraZeneca Transform ADC Dominance Into an $80 Billion Revenue Juggernaut by 2030?
AstraZeneca masterminds an “oncology everywhere” empire through surgical deployment of 20+ late-stage novel molecular entities across oncology (43% revenue), CVRM,…
